The Vigabatrin REMS Program is needed by the FDA to make sure notified risk-benefit decisions before initiating therapy, and to ensure appropriate use of vigabatrin while clients are dealt with. It is not feasible for your healthcare provider to know when vision loss will take place.
The most common side effect of SABRIL in children 3 to 16 years is weight gain. With serious vision loss, you might just be able to see points directly in front of you (often called tunnel vision"). You go to risk for vision loss with any type of quantity of SABRIL.
Inform your doctor if you are expectant or mean to get expectant. If vision screening can not be done, your healthcare provider might proceed prescribing SABRIL, but will certainly not have the ability to expect any vision loss. If vision tests are refrained routinely, your healthcare provider might quit suggesting SABRIL for you (or your child).